Introduction The four members of the p90 ribosomal S6 kinase (RSK) family are
serine/threonine protein kinases, which are phosphorylated and activated by ERK1/2 …

The Serine/Threonine protein kinase family, p90 ribosomal S6 kinases (RSK) are
downstream effectors of extracellular signal regulated kinase 1/2 (ERK1/2) and are activated …

Immunotherapy has achieved tremendous success in melanoma. However, only around
50% of advanced melanoma patients benefit from immunotherapy. Cyclin‐dependent …

Dracaena arborea (DA) and Bridelia ferruginea (BF) are medicinal plants used in the
treatment of various ailments such as diabetes, infertility, and sexual dysfunctions. The aim …

PLK1 inhibitors are emerging anticancer agents that are being tested as monotherapy and
combination therapies for various cancers. Although PLK1 inhibition in experimental models …

Simple Summary Melanoma patients with high neutrophil counts often show impaired
clinical response and poor prognosis, indicating that neutrophils can support melanoma …

Targeted therapy, such as tyrosine kinase inhibitors (TKIs), has been approved to manage
various cancer types. However, TKI-induced cardiotoxicity is a limiting factor for their use …

Recent advances in cancer immunotherapy, especially immune checkpoint inhibitors (ICIs),
have revolutionized the clinical outcome of many cancer patients. Despite the fact that …

PLK1 inhibitors are emerging anti-cancer agents being tested in monotherapy and
combination therapies for various cancers. Although PLK1 inhibition in experimental models …

P90 ribosomal S6 kinase 2 (RSK2) is an important member of the RSK family, functioning as
a kinase enzyme that targets serine and threonine residues and contributes to regulating …